Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | STAT3 | P40763 | 1/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12883160 | 1.00 | ACHE (0.65) | ACHESTAT3FFAR1ALOX5POLB | |
| SCHEMBL16232164 | 0.82 | POLB (0.47) | ACHESTAT3FFAR1POLBALDH1A1 | |
| SCHEMBL7565865 | 0.82 | POLB (0.47) | ACHESTAT3FFAR1POLBALDH1A1 | |
| SCHEMBL16232165 | 0.82 | POLB (0.47) | ACHESTAT3FFAR1POLBALDH1A1 | |
| SCHEMBL25152959 | 0.82 | ACHE (0.67) | ACHESTAT3FFAR1ALOX5POLB | |
| SCHEMBL14731823 | 0.82 | ACHE (0.67) | ACHESTAT3FFAR1ALOX5POLB | |
| SCHEMBL2005344 | 0.82 | FFAR1 (0.51) | FFAR1POLBALDH1A1CYP2C19 | |
| SCHEMBL7559049 | 0.82 | ACHE (0.67) | ACHESTAT3FFAR1ALOX5POLB | |
| SCHEMBL5787675 | 0.82 | FFAR1 (0.51) | FFAR1POLBALDH1A1CYP2C19 | |
| SCHEMBL12883165 | 0.82 | ACHE (0.67) | ACHESTAT3FFAR1ALOX5POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239739-A1 | COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20160137592-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2016-05-19 | — | — | US | disclosed |
| US-9212155-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20110046128-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046128-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GAP43, CHRNA10, CHRNA6 | ACHE 10/4885STAT3 615/4885FFAR1 845/4885 |
| US-20160137592-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, HDAC3 | ACHE 34/4885STAT3 799/4885FFAR1 553/4885 |
| US-20240239739-A1 | COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, CTSA | ACHE 27/4885STAT3 881/4885FFAR1 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.